Evaluating a Streamlined Dual-Phase 68Ga-PSMA PETCT Imaging Protocol to Reduce Radiation in High-risk Prostate Cancer
Led by IRCCS Azienda Ospedaliero-Universitaria di Bologna · Updated on 2026-01-21
244
Participants Needed
1
Research Sites
52 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating a modified dual-phase 68Ga-PSMA PETCT imaging method for patients with high-risk prostate cancer. This study compares a streamlined protocol that reduces radiation exposure and examination time against the standard imaging process. The goal is to maintain high diagnostic quality while improving patient experience and workflow efficiency in the Nuclear Medicine Unit. The trial includes patients newly diagnosed or experiencing biochemical recurrence of prostate cancer, with a focus on those with high-risk disease defined by Gleason Score 28 or PSA 20 ngmL.
Participants are randomly assigned to one of two groups. The control group undergoes the conventional dual-phase PETCT protocol, including a whole-body scan at 60 minutes post-radiotracer injection followed by a delayed pelvic PETCT with CT at 90 minutes. The intervention group receives a standard whole-body PETCT at 60 minutes and a delayed pelvic PET-only scan at 90 minutes, using the initial CT scan for image correction to avoid repeat CT radiation. Patient repositioning is carefully performed to maintain alignment between the PET and CT images.
During the study, three Medical Imaging Technologists independently evaluate the anatomical matching between delayed PET images and the CT dataset. Radiation dose exposure is measured, and patient comfort and waiting times are assessed through questionnaires. Departmental efficiency is monitored using scheduling records. The primary outcome is the quality of PET-CT matching, with secondary outcomes including radiation dose optimization and patient throughput. Participation lasts on average about one year until study completion.
CONDITIONS
Brief Title
Delayed Pelvic Imaging With [68]Ga-PSMA PET/CT in a Patient With High-risk Prostate Cancer.
Research Team
M
Michela Moscarino, Technician
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Lead Sponsor
Who Can Participate
Age: 30Years +
MALE
Eligibility Criteria
You may qualify if you...
Male patients aged 30 years or older
Newly diagnosed prostate cancer undergoing staging, or biochemical recurrence after prior radical-intent therapy
High-risk prostate cancer defined as Gleason Score 28 or PSA 20 ng/mL
Ability to provide written informed consent and authorize personal data processing
You will not qualify if you...
Genitourinary conditions that may interfere with imaging or interpretation
Intermediate- or low-risk prostate cancer
Delayed imaging performed on a different PET/CT scanner than the standard acquisition
Additional PET/CT required due to artifacts affecting diagnostic quality
Previous participation requiring repeat PET/CT as a new visit
Inability to provide informed consent or impaired decision-making capacity
Known allergy to the radiopharmaceutical or its components
Contraindications to PET/CT such as severe claustrophobia, morbid obesity, or inability to cooperate
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Diagnostic Evaluation
Duration - Single day
Participants undergo PET/CT imaging to evaluate prostate cancer using either the standard protocol or the modified dual-phase protocol with delayed pelvic PET imaging.
1 imaging visit including standard whole-body PET/CT at 60 minutes and delayed pelvic PET or PET/CT at 90 minutes
Long-term Monitoring
Duration - Up to 1 year
Participants' imaging results and radiation exposure are assessed, and patient experience is evaluated through questionnaires and institutional records.
Questionnaire administered after imaging visit with follow-up data collected from institutional records
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
DIAGNOSTIC
Number of Arms
2
Similar Trials
Study of Epigenetic Therapy Before Prostate Surgery in Men with High-risk Prostate Cancer
Evaluating Neoadjuvant Capivasertib with Intensified Androgen Deprivation before Radical Prostatectomy for High-Risk Localized Prostate Cancer Showing PTEN Loss
Comparing 177Lu-PSMA-617 and 225Ac-PSMA-617 Radioligand Therapies Before Prostatectomy in High-Risk Prostate Cancer
Evaluating a Streamlined Dual-Phase 68Ga-PSMA PETCT Imaging Protocol to Reduce Radiation in High-risk Prostate Cancer
Phase 2 Study of FK-PC101 Vaccine as Additional Treatment for Men With High-Risk Prostate Cancer After Prostate Surgery
Evaluation of Neoadjuvant Androgen Deprivation Therapy, Darolutamide, and Pembrolizumab Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Risk Prostate Cancer
Phase II Study of HSV-tk and Valacyclovir Gene Therapy Combined with Hormone Therapy, Radiotherapy, and Surgery for High-Risk Prostate Cancer
Study of Serial PSMA PET Scans to Monitor Treatment Response in Newly Diagnosed Clinically Significant Prostate Cancer in Men
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Multiphasic 68Ga-PSMA PET/CT in the Detection of Early Recurrence in Prostate Cancer Patients with a PSA Level of Less Than 1 ng/mL: A Prospective Study of 135 Patients.
Mohsen Beheshti, Reyhaneh Manafi-Farid, Hans Geinitz...